news
TAmiRNA at RNA Society Annual Meeting, 30 May – 4 June 2023, Singapore
TAmiRNA Senior Scientist Dr. Kseniya Khamina-Kotisch will present Poster 46 ‘Identification of novel circulating MicroRNA Biomarkers of Central Nervous System Damage by absolute quantitation using a MicroRNA Next-Generation Sequencing Discovery (miND) Assay’. She will also present Poster 66: ‘Comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs) in cells, plasma, urine, and extracellular vesicles’. Take advantage, meet Kseniya [...]
We are proud to announce our ISO 13485:2016 certification
Today we announce that TAmiRNA has received ISO 13485:2016 certification for its Medical Device and Quality Management System after successfully completing the audit through Germany-based notified body MDC. This ISO certification indicates that TAmiRNAs quality management system meets the most current regulatory requirements applicable to the medical device industry. "We are very proud of this certification as it demonstrates the commitment of our [...]
Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjectsPlasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects
biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring
Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects
We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read [...]
Biogenity Joins Forces with TAmiRNA
The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release
miND spike-in
TAmiRNA has launched an innovative NGS technology for absolute quantitation of miRNAs and other small RNAs , the miND® (microRNA Next-Generation Sequencing Discovery) spike-in. The miND® spike-in has been developed for small RNA sequencing experiments and absolute quantitation of microRNAs in any biological matrix and species, overcoming previous challenges of quality control and difficulty in achieving absolute quantitation of miRNAs across different biological [...]
hepatomiR kit
TAmiRNA has launched its latest hepatomiR® CE-IVD testing kit that can measure levels of three important liver-enriched microRNAs (liver miRNAs) in human blood to determine a patient’s liver function. TAmiRNA’s microRNA-based hepatomiR® kit is worldwide the first approved CE-IVD test to measure microRNA liver biomarkers in human plasma. The new microRNA-based hepatomiR® technology represents a milestone previously restricted to research use only (RUO) [...]
miRNA NGS Discovery pipeline – miND
TAmiRNA present microRNA Next-Generation-Sequencing Discovery Assay (miND), a novel panel of exogenous small RNA spike-in controls that enables quality control and absolute quantitation of NGS data. Eager to learn more - have a look at our two new publications! click here for more Information on the novel wet-lab small RNA-seq workflow and here for more insights into the bioinformatic pipeline [...]
TAmiRNA is hiring
TAmiRNA is searching for new team members. You are looking for a new Job feel free to apply! Head of Business Development - for more information click HERE
New study using TAmiRNAs SARS-CoV-2 Antibody Test (Lateral Flow Method)
The aims of the study was to determine: (i) SARS-CoV-2 antibody positive employees in Austrian trauma hospitals and rehabilitation facilities, (ii) number of active virus carriers (symptomatic and asymptomatic) during the study (iii) antibody decline in seropositive subjects over a period of around 6 months and (iv) the usefulness of rapid antibody tests for outpatient screening. To find out more about TAmiRNAs SARS-CoV-2 [...]
TAmiRNA shares microRNA biomarker insights at FIDELIO training webinarTAmiRNA shares microRNA biomarker insights at FIDELIO training webinar
aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, diabetes, microRNAs, microstructure, osteoporosis, Personalized medicine, type 2 diabetes mellitus
TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar
TAmiRNA is a key partner in the EU-funded Innovative Training Network FIDELIO, which aims to train the next generation of scientists in tackling the challenges of bone fragility in diabetic patients. The webinar "MicroRNAs: small RNAs with big potential as biomarkers and drug targets in bone diseases" is a one-hour session hosted by TAmiRNA founder and CEO Dr. Matthias Hackl. He show how [...]